secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001193125-25-178949
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta reports Q2 net loss of $23M, cash of $334M; NKX019 data expected H2 2025
-------------------------------------------------------------------------------

- Net loss of $23.0M ($0.31 per share) for Q2 2025.
- Cash, equivalents and investments of $334.0M as of June 30, 2025; runway into 2029.
- R&D expenses of $20.8M; G&A expenses of $6.4M for Q2 2025.
- Preliminary NKX019 autoimmune data (Ntrust-1 and Ntrust-2) expected H2 2025.
- Shawn Rose, M.D., Ph.D appointed Chief Medical Officer and Head of R&D in June 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000119312525178949/0001193125-25-178949-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000119312525178949/nktx-20250812.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-178949

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer